These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 29307892)

  • 41. Meta-analysis of Dedicated Renal Outcome Trials Assessing the Cardio-renal Efficacy of Sodium-Glucose Co-transporter-2 Inhibitors in Patients With Chronic Kidney Disease and Albuminuria.
    Patoulias D; Papadopoulos C; Stavropoulos K; Imprialos K; Doumas M
    Am J Cardiol; 2021 Jan; 138():116-118. PubMed ID: 33045203
    [No Abstract]   [Full Text] [Related]  

  • 42. Obesity Week 2016 Annual Meeting.
    Marathe PH; Dove AE; Gao HX; Odeh SA; Close KL
    J Diabetes; 2017 Mar; 9(3):215-218. PubMed ID: 27883282
    [No Abstract]   [Full Text] [Related]  

  • 43. Obesity in 2015: Advances in managing obesity.
    Dixon JB
    Nat Rev Endocrinol; 2016 Feb; 12(2):65-6. PubMed ID: 26729038
    [No Abstract]   [Full Text] [Related]  

  • 44. A Review of Sodium Glucose Co-transporter 2 Inhibitors Canagliflozin, Dapagliflozin and Empagliflozin.
    Syed SH; Gosavi S; Shami W; Bustamante M; Farah Z; Teleb M; Abbas A; Said S; Mukherjee D
    Cardiovasc Hematol Agents Med Chem; 2015; 13(2):105-12. PubMed ID: 26549321
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [In patients with type 2 diabetes and diabetic nephropathy with albuminuria, what is the effect of SGLT2 inhibitor canagliflozin on renal and cardiovascular outcomes?].
    Lanthier L; Huard G; Plourde MÉ; Cauchon M
    Rev Med Interne; 2020 Jan; 41(1):67-68. PubMed ID: 31812446
    [No Abstract]   [Full Text] [Related]  

  • 46. Two cases of advanced stage rapidly progressive diabetic nephropathy effectively treated with combination therapy including RAS blocker, GLP-1 receptor agonist and SGLT-2 inhibitor.
    Morino J; Hirai K; Kaneko S; Minato S; Yanai K; Mutsuyoshi Y; Ishii H; Matsuyama M; Kitano T; Shindo M; Aomatsu A; Miyazawa H; Ito K; Ueda Y; Hoshino T; Ookawara S; Hara K; Morishita Y
    CEN Case Rep; 2019 May; 8(2):128-133. PubMed ID: 30663011
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sodium glucose transporter 2 inhibition: a new approach to diabetes treatment.
    Bloomgarden Z
    J Diabetes; 2013 Sep; 5(3):225-7. PubMed ID: 23714218
    [No Abstract]   [Full Text] [Related]  

  • 48. Reconceptualization of the Molecular Mechanism by Which Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Events.
    Packer M
    Circulation; 2019 Aug; 140(6):443-445. PubMed ID: 31381418
    [No Abstract]   [Full Text] [Related]  

  • 49. European Association for the Study of Diabetes 51st Annual Meeting.
    Gao HX; Regier EE; Close KL
    J Diabetes; 2016 Mar; 8(2):177-80. PubMed ID: 26606912
    [No Abstract]   [Full Text] [Related]  

  • 50. Earlier onset of treatment improves the nephroprotective effect of dapagliflozin.
    Gippini A; Prado A
    Nefrologia (Engl Ed); 2024; 44(3):431-433. PubMed ID: 39002997
    [No Abstract]   [Full Text] [Related]  

  • 51. Ketonuria/ketonemia associated with the use of sodium-glucose cotransporter 2 (SGLT-2) inhibitors in type 2 diabetes: A report of three cases from New Delhi, India.
    Ghosh A; Gupta R; Misra A
    J Diabetes; 2016 Sep; 8(5):738-9. PubMed ID: 27085074
    [No Abstract]   [Full Text] [Related]  

  • 52. Antidiabetic Drug Approved to Reduce Risk of Kidney Disease.
    Aschenbrenner DS
    Am J Nurs; 2021 Sep; 121(9):25. PubMed ID: 34438427
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of SGLT Inhibitors on Multiple Organ Defects in Diabetes.
    Asrih M; Gariani K
    Curr Diabetes Rev; 2020; 16(5):411-418. PubMed ID: 31702506
    [TBL] [Abstract][Full Text] [Related]  

  • 54. SGLT2 inhibitors: new reports.
    Med Lett Drugs Ther; 2015 Oct; 57(1479):139-40. PubMed ID: 26445203
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Weight Outcomes With Empagliflozin as Compared With Liraglutide in Veterans With Type 2 Diabetes Mellitus.
    Grabarczyk TR; Wissman NK
    Ann Pharmacother; 2020 Oct; 54(10):981-987. PubMed ID: 32274930
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of 3-month therapy with empagliflozin on ambulatory blood pressure and arterial stiffness in patients with type 2 diabetes mellitus.
    Papazafiropoulou AK; Mpoumi L; Papantoniou S; Rallatou M; Antonopoulos S; Melidonis A
    Ann Afr Med; 2021; 20(2):154-155. PubMed ID: 34213486
    [No Abstract]   [Full Text] [Related]  

  • 57. SGLT2 inhibitors and renal function.
    Med Lett Drugs Ther; 2016 Jul; 58(1499):91-2. PubMed ID: 27403782
    [No Abstract]   [Full Text] [Related]  

  • 58. Real world points to SGLT-2 blockers advantage.
    Nat Biotechnol; 2017 Apr; 35(4):297. PubMed ID: 28398306
    [No Abstract]   [Full Text] [Related]  

  • 59. [The role of SGLT-2 inhibitors in the treatment of type 2 diabetes].
    Rupprecht H
    MMW Fortschr Med; 2015 Jan; 157(1):55-8. PubMed ID: 25743304
    [No Abstract]   [Full Text] [Related]  

  • 60. EMPA-REG OUTCOME: The Nephrologist's Point of View.
    Wanner C
    Am J Med; 2017 Jun; 130(6S):S63-S72. PubMed ID: 28526179
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.